Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

Web of Science 3 Crossref 3

DOI: https://doi.org/10.3350/cmh.2022.0017

Management of refractory ascites

Florence Wong

Clin Mol Hepatol. 2023;29(1):16-32. Published online June 9, 2022

Web of Science 10 Crossref 11

DOI: https://doi.org/10.3350/cmh.2022.0104

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

Web of Science 8 Crossref 9

DOI: https://doi.org/10.3350/cmh.2022.0058

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

Web of Science 10 Crossref 11

DOI: https://doi.org/10.3350/cmh.2022.0095

Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment

Soo-Jeung Park, Young S. Hahn

Clin Mol Hepatol. 2023;29(1):65-76. Published online August 12, 2022

Web of Science 8 Crossref 9

DOI: https://doi.org/10.3350/cmh.2022.0032

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

Web of Science 24 Crossref 33

DOI: https://doi.org/10.3350/cmh.2022.0237

Editorials

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(1):99-101. Published online October 27, 2022

Web of Science 3 Crossref 3

DOI: https://doi.org/10.3350/cmh.2022.0321

The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(1):102-104. Published online November 10, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0353

Non-invasive tests-based risk stratification: Baveno VII and beyond

Georg Semmler, Mathias Jachs, Mattias Mandorfer

Clin Mol Hepatol. 2023;29(1):105-109. Published online November 23, 2022

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2022.0361

Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey

Susana G Rodrigues

Clin Mol Hepatol. 2023;29(1):110-112. Published online December 12, 2022

Web of Science 1 Crossref 2

DOI: https://doi.org/10.3350/cmh.2022.0414

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022

Web of Science 3 Crossref 3

DOI: https://doi.org/10.3350/cmh.2022.0333

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2022.0413

Original Articles

Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly

Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):120-134. Published online August 12, 2022

Web of Science 17 Crossref 17

DOI: https://doi.org/10.3350/cmh.2021.0395

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients

Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):135-145. Published online September 5, 2022

Web of Science 11 Crossref 14

DOI: https://doi.org/10.3350/cmh.2022.0181

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

Web of Science 9 Crossref 9

DOI: https://doi.org/10.3350/cmh.2022.0172

Letters to the Editor

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Yuanbin Liu, Mingkai Chen

Clin Mol Hepatol. 2023;29(1):163-164. Published online October 27, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0326

Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Do Seon Song, U Im Chang, Jin Mo Yang

Clin Mol Hepatol. 2023;29(1):165-167. Published online October 31, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0339

Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Clin Mol Hepatol. 2023;29(1):168. Published online October 31, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0328

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0384

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Seung Min Lee, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):171-172. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0381

Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim

Clin Mol Hepatol. 2023;29(1):173-175. Published online November 15, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0372

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2023;29(1):176-178. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0377

Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):179-181. Published online November 22, 2022

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2022.0409

Correspondences

Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”

Won Sohn, Yong-Han Paik

Clin Mol Hepatol. 2023;29(1):182-184. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0411

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):185-187. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0375

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):188-190. Published online November 22, 2022

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2022.0408

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”

Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):191-193. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0410

Snapshot

Epidemiology and updated management for autoimmune liver disease

Nae-Yun Heo, Haeryoung Kim

Clin Mol Hepatol. 2023;29(1):194-196. Published online December 14, 2022

Web of Science 2 Crossref 4

DOI: https://doi.org/10.3350/cmh.2022.0387

Viewed By 5251	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5192	MAFLD: How is it different from NAFLD?
Viewed By 5102	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3823	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3752	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Previous issues